(2) EBITDA defined as operating income before depreciation and amortization Net Sales: Like-for-like sales declined -3.9%, reflecting weak consumption in Mexico and disruptions in the U.S. Hispanic ...

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and ...

MEXICO CITY, Dec. 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies ...

Agreement Combines Procaps Oral Delivery System Technology and Manufacturing with Genomma’s Strategic Marketing and Distribution Footprint “We’re excited to partner with Genomma, as this collaboration ...

HOUSTON--(BUSINESS WIRE)--As consumers continue to adapt their behaviors due to the COVID-19 pandemic, offering quality and known products that can help them with their day-to-day life in the “new ...

Consolidated Net Sales: MXN17.5 billion for full-year 2025, a 5.7% year-on-year decline. Fourth-Quarter Net Sales: MXN4 billion, a 13.9% decrease versus prior year. EBITDA Margin: Expanded 43 basis ...

IRVINGTON, N.Y. — Genomma Lab is planning to present a list of candidates to serve on the board of directors of Prestige Brands. The announcement followed Genomma Lab's unsolicited proposal to acquire ...

Genomma Lab InternacionalB. De C.v. is trading at $1.08 per share. As of the most recent reporting period, Genomma Lab InternacionalB. De C.v. reported total debt of MX$452.29M. How much cash does ...

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the ...

para este a +/-o, arrastrando a la baja sus acciones. Los t -tulos de Genomma ca -an un 2.23 por ciento en la bolsa mexicana a 25.43 pesos a las 10.41 hora local. Las p (c)rdidas se sumaban a la baja ...

Like-for-like ("LFL") sales: when adjusted into constant currency and excluding the hyperinflationary subsidiary, sales increased by 9.7% reflecting a double-digit increase in six out of nine core ...